Literature DB >> 9486001

Changes in bone mineral density in patients with Paget's disease treated with risedronate.

S Patel1, D Pearson, A Bhallah, W Maslanka, D A White, D J Hosking.   

Abstract

OBJECTIVES: To study changes in bone mineral density (BMD) in patients with Paget's disease of bone treated with risedronate.
METHODS: Whole body dual energy x ray absorptiometry (DXA) scans were carried out on 20 patients with Paget's disease treated with oral risedronate. DXA scanning was carried out at baseline and 11 months. Whole body bone mineral content (BMC) was measured. In addition, regions of interest were drawn around the skull, individual lumbar vertebrae, hemipelvis, femora, and tibiae to obtain BMD for these sites. An uncoupling index was also calculated as the area under the curve for serum alkaline phosphatase (ALP) divided by the area under the curve for hydroxyproline excretion (HYPRO) for the period of treatment.
RESULTS: Median whole body BMC increased from 3057 g to 3156 g (p < 0.001) resulting from an increase in pagetic and non-pagetic BMD. From the analysis of regions of interest it was found that pagetic trabecular bone showed the largest increase in BMD. The pretreatment HYPRO and the uncoupling index were significantly related to the change in BMD for all pagetic sites for a patient (r = 0.65, p < 0.01 and r = 0.57, p < 0.05 respectively).
CONCLUSION: Bisphosphonate treatment of Paget's disease results in an increase in BMD of pagetic bone without redistribution of mineral from non-pagetic bone. The remodelling space and extent of uncoupling are significantly related to increases in BMD at pagetic sites.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9486001      PMCID: PMC1752415          DOI: 10.1136/ard.56.7.405

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Precision of total-body and regional bone mineral measurement by dual-energy X-ray absorptiometry.

Authors:  H Seto; M Kageyama; K Nomura; M Kakishita; S Tonami
Journal:  Radiat Med       Date:  1991 May-Jun

2.  Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.

Authors:  A Carano; S L Teitelbaum; J D Konsek; P H Schlesinger; H C Blair
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

3.  Skeletal renewal and metabolic bone disease.

Authors:  W H Harris; R P Heaney
Journal:  N Engl J Med       Date:  1969-01-23       Impact factor: 91.245

4.  Prospective use of bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  J Clin Endocrinol Metab       Date:  1993-06       Impact factor: 5.958

Review 5.  Current and potential future drug treatments for osteoporosis.

Authors:  S Patel
Journal:  Ann Rheum Dis       Date:  1996-10       Impact factor: 19.103

6.  Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.

Authors:  M Sahni; H L Guenther; H Fleisch; P Collin; T J Martin
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

7.  Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium.

Authors:  R I Price; D H Gutteridge; B G Stuckey; G N Kent; R W Retallack; R L Prince; C I Bhagat; C A Johnston; G C Nicholson; G O Stewart
Journal:  J Bone Miner Res       Date:  1993-02       Impact factor: 6.741

8.  Total body and regional bone mineral analysis by dual-photon absorptiometry in Paget's disease of bone.

Authors:  R Nuti; G Righi; V Turchetti; G Martini; C Lepore
Journal:  Bone Miner       Date:  1988-03

9.  Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone.

Authors:  A M Flanagan; T J Chambers
Journal:  Bone Miner       Date:  1989-04

10.  Diphosphonates inhibit human osteoblast secretion and proliferation.

Authors:  M A Khokher; P Dandona
Journal:  Metabolism       Date:  1989-02       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.